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ochi and Tokyo, Japan
OBJECTIVES We studied the longitudinal evolution of hypertrophic cardiomyopathy (HCM) caused by a
founder frameshift mutation in the cardiac myosin-binding protein C (MyBPC) gene.
BACKGROUND Mutations in the MyBPC gene have been associated with delayed expression of HCM and
a good prognosis. Few studies, however, demonstrated the phenotype-genotype correlations
in the longitudinal study.
METHODS We studied long-term evolution of clinical features of 15 unrelated families who were found
to have an identical frameshift mutation in the MyBPC gene: a one-base deletion of a
thymidine at nucleotide 11645 (V592fs/8).
RESULTS Thirty-nine individuals in 15 families were genotype-positive. Thirty of the 39 individuals
with the mutation were phenotype-positive. The disease penetrance was 100% in subjects
50 years and 65% in those 50 years. “End-stage” HCM (ejection fraction 50%) was
observed in 7 (18%) of the 39 genotype-positive individuals (7 [23%] of the 30 phenotype-
positive patients); 6 of them were 60 years or older. Seven patients were hospitalized for
treatment of repeated congestive heart failure, and four patients died or had implantable
cardioverter-defibrillator discharge (13%; incidence, 1.4%/year) during a mean follow-up
period of 9.2  5.5 years.
CONCLUSIONS Elderly patients with a V592fs/8 mutation in the MyBPC gene may evolve into the
“end-stage” HCM, characterized by left ventricular systolic dysfunction, cavity dilation, and
irreversible heart failure. The clinical course in patients with this mutation is not benign in
the long run, with progressive left ventricular remodeling with advancing age. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.087Cardiol 2005;46:1737–43) © 2005 by the American College of Cardiology Foundation
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Sypertrophic cardiomyopathy (HCM) is a primary myo-
ardial disorder with heterogeneous morphologic, func-
ional, and clinical features (1–4). Recent molecular genetic
tudies have revealed that HCM is caused by mutations in
0 genes that encode sarcomeric contractile proteins (5–9).
See page 1744
ardiac myosin-binding protein C (MyBPC) is one of these
arcomeric proteins, and mutations in the MyBPC gene have
een reported to be associated with delayed expression of
ypertrophy and a relatively good prognosis (10–14). On the
ther hand, a recent report showed that patients with muta-
From the *Department of Medicine and Geriatrics, Kochi Medical School, Kochi,
apan, and the †Medical Research Institute, Tokyo Medical and Dental University,
okyo, Japan. The study was supported in part by Grant-in-Aid for Scientific
esearch, The Ministry of Education, Culture, Sports, Science, and Technology
KAKENHI 16590693, 12204004, 15659182, 16390219), and a research grant from
he Ministry of Health, Labour, and Welfare.s
Manuscript received January 17, 2005; revised manuscript received April 25, 2005,
ccepted May 25, 2005.ions in the MyBPC gene did not differ significantly from
atients with thick-filament HCM or thin-filament HCM
ith respect to age at diagnosis or severity of phenotype (15).
Few studies, however, have demonstrated longitudinal
volution of phenotype in relation to genotype, although the
CM phenotype itself is recognized to be a slowly progres-
ive disorder that manifests remarkable evolution of clinical
eatures throughout life (16).
We analyzed the MyBPC gene in probands from families
ith HCM and had the opportunity to study 15 unrelated
amilies living in Kochi prefecture, Japan, who were found
o have an identical frameshift mutation in the MyBPC
ene: a one-base deletion of a thymidine at nucleotide
1645 (V592fs/8) (17). The results of clinical and genetic
nvestigations in these 15 families during a long period of
ime are presented herein.
ETHODS
ubjects. The subjects were 94 probands with familial or
poradic HCM. Twenty-two subjects were familial HCM,
w
r
K
n
1
e
v
u
p
i
o
c
f
p
C
C
t
e
l
c
o
m
l
t
d
s
f
d
c
s
u
w
c
m
d
l
E
c
w
m
u
w
o
r
d
p
p
i
d
e
G
t
s
fi
m
f
p
I
r
w
i
C
P
t
m
f
m
c
w
r
e
fl
t
p
R
G
t
i
w
p
6
g
b
a
c
w
a
c
u
D
V
c
1738 Kubo et al. JACC Vol. 46, No. 9, 2005
Lifelong LV Remodeling of HCM November 1, 2005:1737–43hereas the other 72 subjects were not confirmed to have
elatives with HCM. All probands were evaluated at the
ochi Medical School Hospital for confirmation of diag-
osis, risk assessment, and symptom management between
982 and 2004. The diagnosis of HCM was based on
chocardiographic demonstration of an unexplained left
entricular hypertrophy (LVH) (i.e., maximum left ventric-
lar wall thickness [MLVWT] 15 mm). Relatives of
robands were contacted by probands themselves and vis-
ted our clinic of their own free will. After the identification
f a V592fs/8 mutation, pedigree analysis, including both
linical evaluation and genotyping, was performed. In-
ormed consent was obtained from all subjects or their
arents in accordance with the guidelines of the Ethics
ommittee on Medical Research of Kochi Medical School.
linical evaluation. The evaluation of probands and rela-
ives included medical history, clinical examination, 12-lead
lectrocardiography, M-mode, two-dimensional and Dopp-
er echocardiography, and ambulatory 24-h Holter electro-
ardiographic (ECG) analysis. The severity and distribution
f LVH were assessed in the parasternal short-axis plane at
itral valve and papillary muscle levels (18,19). Maximum
eft ventricular wall thickness was defined as the greatest
hickness in any single segment. Left ventricular end-diastolic
iameter (LVEDD) and end-systolic diameter were mea-
ured from M-mode and two-dimensional images obtained
rom parasternal long-axis views. Ejection fraction (EF) was
etermined from apical two- and four-chamber views be-
ause the left ventricle is of heterogeneous shape and the
eptum itself is usually hypokinetic in HCM. Left ventric-
lar outflow tract gradient was calculated from continuous-
ave Doppler using the simplified Bernoulli equation.
Disease penetrance was determined by the following
riteria for relatives: 1) MLVWT 13 mm; 2) presence of
ajor abnormalities on the ECG (i.e., Q-wave 0.04 s in
uration or one-fourth of the ensuing R-wave in depth in at
east two leads, significant ST-T changes, and Romhilt-
stes score 4); or 3) a combination of criteria 1 and 2.
Data regarding survival and clinical status of patients were
ollected during serial clinic visits. Evaluation of the phenotype
as completed before determination of the genotype. Three
odes of HCM-related death were defined: 1) sudden and
nexpected death (including resuscitated cardiac arrest), in
Abbreviations and Acronyms
AF  atrial fibrillation
ECG  electrocardiogram/electrocardiographic
EF  ejection fraction
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LVEDD  left ventricular end-diastolic diameter
LVH  left ventricular hypertrophy
MLVWT  maximum left ventricular wall thickness
MyBPC  cardiac myosin-binding protein Chich the collapse occurred in the absence or 1 h from the fnset of symptoms in patients who previously experienced a
elatively stable or uneventful course; 2) heart failure-related
eath, which was in the context of progressive cardiac decom-
ensation 1 year before death, particularly if complicated by
ulmonary edema or evolution to the end-stage phase (includ-
ng patients with heart transplantation); and 3) stroke-related
eath, which occurred in patients who died as a result of
mbolic stroke.
enetic analysis. Peripheral blood samples were taken at
he time of clinical evaluation, and they were frozen and
tored at 20°C. We extracted DNA using a DNA puri-
cation kit from QIAGEN Inc. (no.51104; Hilden, Ger-
any). In vitro amplification of genomic DNA was per-
ormed using polymerase chain reaction. Oligonucleotide
rimers were used to amplify exon 18 of the MyBPC gene.
nformation on primer sequences and polymerase chain
eaction conditions is available upon request. Sequencing
as performed using a BigDye Terminator Cycle Sequenc-
ng Kit from Applied Biosystems Inc. (no.4336774; Foster
ity, California). The sequences were analyzed on an ABI
RISM 3100-Avant Genetic Analyzer in accordance with
he manual of the manufacturer.
In patients in whom the mutation was identified, confir-
ation was obtained by reanalysis with direct sequencing
rom a second blood sample. The presence of a V592fs/8
utation, which abolishes a BsmFI restriction site, was
onfirmed by digestion of genomic DNA with this enzyme.
To investigate if families carrying the identical mutation
ere related, haplotype analysis was performed using mic-
osatellite markers defining the MyBPC gene locus. Mark-
rs MyBPC3-CA, D11S4109, D11S1784, and D11S1326,
anking the MyBPC gene, were used. To describe haplo-
ype results, the length (base pair) of allele was put in
arentheses after each marker.
ESULTS
enetic results. A V592fs/8 mutation, a frameshift muta-
ion that causes truncation of cardiac MyBPC protein, was
dentified in 15 of 94 probands. Relatives of 15 probands
ere studied further, totaling 64 members, including 15
robands, of the various families (Figs. 1A to 1G). Of the
4 individuals, 39 had a V592fs/8 mutation in the MyBPC
ene. This mutation was thought to be disease-causing
ased on presence of the mutation in all affected individuals
nd absence of the sequence variation in at least 200
hromosomes from healthy individuals.
Haplotype analysis with highly polymorphic markers
as performed in these families to investigate whether
V592fs/8 mutation was likely to have arisen from a
ommon ancestor (founder effect). We found that a
nique haplotype, MyBPC3-CA(282)-D11S4109(151)-
11S1784(138)-D11S1326(249), was linked to the
592fs/8 mutation in all 15 families, indicating that a
ommon founder of the mutation was likely in these
amilies.
F
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November 1, 2005:1737–43 Lifelong LV Remodeling of HCMigure 1. (A to G) Pedigree of families H007, H008, H011, H015, H027, H034, H037, H041, H047, H048, H061, H067, H074, H086, and H090. The
enotypic status and phenotypic status of subjects are indicated.
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Lifelong LV Remodeling of HCM November 1, 2005:1737–43linical manifestation. Clinical evaluation was performed
n the 64 individuals from the 15 proband families studied.
he mean follow-up period in the all 39 genotype-positive
ndividuals was 8.0  5.4 years (range, 0.2 to 19.3 years).
hirty patients were phenotype-positive, all with echocar-
iographic evidence of LVH. Two adults developed hyper-
rophy (MLVWT13 mm) after the age of 40. Nine of the
9 individuals were not affected phenotypically (average age
t last evaluation: 33 11 years; range, 12 to 43 years). The
isease penetrance was 100% in subjects50 years and 65%
n those 50 years of age.
The clinical characteristics of the 30 phenotype-positive
atients at presentation were summarized in Table 1. The
ge at diagnosis was 47  15 years. Most patients (86%)
ere evaluated because of symptoms or family screening of
CM. A total of 19 patients (63%) reported cardiac
ymptoms. Table 2 shows the echocardiographic character-
stics of the 30 phenotype-positive patients at presentation
nd at last follow-up. At presentation, MLVWT was 21 
.3 mm. Six (20%) of those 30 patients had systolic anterior
ovement of the mitral valve, and three (10%) showed a
ignificant LV outflow tract gradient (pressure gradient at
est 30 mm Hg).
Sudden death occurred in six individuals from four
amilies (Fig. 1; families H015, H047, H086, and H090).
hree individuals were from one family. Five of them were
lder than 50 years of age.
linical course. During a mean follow-up period of 9.2 
.5 years after the first clinical evaluation, paroxysmal or
hronic atrial fibrillation (AF) was detected in 10 (33%;
ncidence, 3.6%/year) of the 30 phenotype-positive patients,
ight of whom were 60 years of age or older. Two of those
atients experienced severe embolic stroke, which was the
ause of their death at the ages of 61 and 68 years,
espectively. One patient (H015-II-2) was on oral antico-
gulation with warfarin. In the other patient (H086-III-1),
able 1. Clinical Characteristics of 30 Phenotype-Positive
atients at Presentation
ge at presentation, yrs (range) 48  14 (16–83)
ender: male, n (%) 17 (57)
ge at diagnosis, yrs (range) 47  15 (14–76)
eason for diagnosis, n (%)
Symptoms 16 (53)
Incidental findings 4 (13)
Family or gene screening 10 (33)
resence of symptoms, n (%) 19 (63)
Dyspnea, n (%) 14 (47)
Palpitation, n (%) 11 (37)
Syncope, n (%) 3 (10)
Chest pain, n (%) 7 (23)
YHA functional class
I 16 (53)
II 10 (33)
III and IV 4 (13)
istory of AF (chronic or paroxysmal) 4 (13)
ata shown as mean value  SD or number (%).
AF  atrial fibrillation; NYHA  New York Heart Association.F was detected at the time of the stroke for the first time.
h
vFigure 2 shows longitudinal changes in LVEDD,
jection fraction (EF), and MLVWT in each of the 39
enotype-positive individuals. Figure 2A shows that
VEDD gradually became larger with advancing age. On
he other hand, LV systolic function was preserved until
iddle age. After middle age, reduction of EF occurred
n some patients (Fig. 2B). “End-stage” HCM (EF
50%) was observed in seven (18%) of the 39 individuals;
ix of them were 60 years or older. Five of them showed
VEDD 55 mm. Figure 2C shows that MLVWT was
hinner in elderly patients than in young patients with
CM and that it was within normal limits in the
henotype-negative individuals.
Table 3 shows the clinical characteristics of seven patients
ith “end-stage” HCM. More specifically, the average age
hen they were first identified as in the end-stage phase was 60
ears (range, 46 to 70 years). Three patients (H011-II-8,
015-II-3, and H086-III-1) were already in the end-stage
hase at presentation. The other four patients progressed to
end-stage” HCM during follow-up. Regarding the cause of
V systolic dysfunction, none of them was considered to have
therosclerotic coronary artery disease because three of them
H007-II-2, H011-II-8 and H086-III-1) had normal coro-
ary angiography, and the remaining four patients had normal
hallium-201 myocardial scintigraphy. No one suffered from
yocardial infarction. All patients with “end-stage” HCM
howed deterioration of New York Heart Association func-
ional class together with a development of paroxysmal or
hronic AF at last follow-up. All of them were treated for heart
ailure and/or arrhythmias: diuretics (n  6), angiotensin-
onverting enzyme inhibitors or angiotensin receptor blockers
n 5), beta-blockers (n 3), and amiodarone (n 2). One
atient (H007-II-2), who was on amiodarone (maintenance
ose 100 to 200 mg/day) for sustained ventricular tachycardia
or 10 months, received an implantable cardioverter-
able 2. Echocardiographic Characteristics of 30 Phenotype-
ositive Patients
At Presentation
At Last
Follow-Up
ge, yrs 48  14 (16–83) 56  15 (28–83)
LVWT, mm 21  5.3 (13–38) 21  6.0 (13–39)
VST, mm 19  4.7 (11–28) 18  4.9 (10–32)
WT, mm 11  1.7 (7–14) 11  2.3 (7–19)
eft atrial diameter, mm 40  8.3 (27–60) 46  9.0 (30–69)
V end-diastolic diameter, mm 44  7.4 (29–64) 47  8.1 (37–67)
V end-systolic diameter, mm 27  7.8 (12–48) 31  9.2 (21–55)
jection fraction, % 66  9.9 (36–85) 61  13.9 (22–81)
radient 30 mm Hg, n (%) 3 (10) 2 (7)
AM, n (%) 6 (20) 6 (20)
attern of LVH, n
Asymmetric 27 27
Diffuse 2 1
Apical 0 0
Others 1 2
ata shown as mean value  SD (range) or number (%).
IVST interventricular septal wall; LV left ventricular; LVH left ventricularypertrophy; MLVWT  maximum left ventricular wall thickness; PWT  left
entricular posterior wall thickness; SAM  systolic anterior movement.
Figure
individ
end-di
(C
)
C
h
T ge” HCM
cardiography at Initial Evaluation/
at Last Evaluation
NYHA Functional
Class, Initial
to Last
Rhythm,
Initial to
Last
Hospitalization
for CHF
(Age, yrs)
Status
(Event Age, yrs)
LVEDD
(mm)
EF
(%)
MLVWT
(mm)
H 49/58 62/22 17/14 I to III SR to AF  (69) ICD discharge (76)
H 49/58 74/30 28/17 I to III SR and PAF  (46) Alive
H 64/62 48/25 15/17 II to III SR to AF  (63) Alive, CRT, MVR
H 56/67 36/37 20/18 II to IV AF to AF  (54) CHF death (73)
H 42/42 66/46 10/20 II to III SR to AF  (60) Stroke death (61)
H 41/46 65/49 18/17 I to III SR to AF — Alive
H 47/55 43/40 20/18 II to III SR to AF  (64) Stroke death (68)
A nization therapy; EF  ejection fraction; LVEDD  left ventricular end-diastolic diameter; MLVWT  maximum left ventricular wall thickness;
M paroxysmal AF; SR  sinus rhythm.
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able 3. Clinical Characteristics of Seven Patients With “End-Sta
Patient Gender
Age (yrs) at
Diagnosis
Age (yrs) at
End-Stage
Echo
Age
(yrs)
007-II-2 M 65 70 65/78
007-III-2 F 14 46 35/47
011-II-8 M 40 58 58/68
015-II-3 M 54 54 54/73
015-II-2 F 45 60 45/60
034-II-1 F 46 68 52/68
086-III-1 F 64 64 64/67
F  atrial fibrillation; CHF  congestive heart failure; CRT  cardiac resynchro
VR  mitral valve replacement; NYHA  New York Heart Association; PAF 
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Lifelong LV Remodeling of HCM November 1, 2005:1737–43efibrillator (ICD) because of amiodarone-induced pulmonary
brosis. One patient (H011-II-8) underwent mitral valve
eplacement and cardiac resynchronization therapy for
edically-refractory heart failure.
During follow-up (9.2 5.5 years), seven (23%) of the 30
atients (mean age: 62  10 years; range, 46 years to 76
ears) were hospitalized for treatment of heart failure, and
our patients died or had ICD discharge (one heart failure-
eath, two stroke-deaths, one ICD discharge; 13%; inci-
ence, 1.4%/year) (Table 3).
ISCUSSION
ypertrophic cardiomyopathy is a heterogeneous myocardial
isorder and the phenotype is not a static manifestation; LVH
an appear at virtually any age and increase or decrease
ynamically throughout life (16,20). However, there have been
ew studies on the phenotype-genotype correlation in terms of
ongitudinal clinical evaluation. In this study, we examined the
linical courses of patients with a founder mutation (V592fs/8)
n the MyBPC gene from 15 unrelated proband families. We
bserved the longitudinal evolution of phenotype caused by
his mutation and concluded that the patients with this
utation were likely to progress to “end-stage” HCM, char-
cterized by LV systolic dysfunction and cavity dilation, with
dvancing age. To the best of our knowledge this is the first
eport demonstrating direct longitudinal evolution of pheno-
ype in relation to genotype.
isease penetrance and clinical manifestation. In the
resent study, the mean age of patients at diagnosis was
7  15 years. During follow-up, two adults showed
evelopment of LVH in mid-life, appearing for the first
ime after 40 years of age. We found that disease penetrance
as 100% in subjects50 years and 65% in those50 years
f age. Our data are in accordance with previously reported
ata for MyBPC mutations (12,14,21–24). Onset of the
isease seems to be late in life, although two patients are
iagnosed as having the disease at teenagers (H007-III-2
nd H047-III-1). These findings indicate that relatives of
he patients, even if they are old, should be screened for this
utation. If genetic diagnosis is not available, middle-aged
r older relatives of the patients should be evaluated at least
very five years for family-screening strategies (2–4,14,25).
rom a morphologic point of view, the degree of MLVWT
aried significantly (13 to 38 mm). None of the subjects
howed apical hypertrophy. Sudden death occurred in six
ndividuals from four families in the present study. It is
otable that most of sudden deaths occurred in subjects50
ears of age (83%; five of the six individuals) because sudden
eath occurs most commonly in children and young adults,
lthough the risk extends across a wide age range through
id-life and beyond (3,26,27).
linical course and prognosis. It was previously sug-
ested that LV remodeling involving some degree of LV
avity enlargement and wall thinning could occur slowly
ver the course of decades (28 –32), although direct congitudinal evidence in relation to gene abnormality was
nsufficient. In the present study, we were able to dem-
nstrate longitudinal LV remodeling in those with a
592fs/8 mutation and also evolution to “end-stage”
CM in the elderly (Fig. 2). HCM generally has been
ssociated with only mild disability and normal life
xpectancy if sudden death can be avoided (27,33–35). In
his study, the clinical manifestation caused by this
utation was late onset and prognosis was not poor in
erms of survival (4 [13%] of the 30 patients died or had
CD discharge; incidence, 1.4%/year). However, a sig-
ificant subset of the patients is likely to suffer from
CM-related cardiovascular events (repeated heart fail-
re, stroke, and sudden death) later in their lives. The
linical course in patients with this mutation is therefore
ot benign in the long run, and careful management is
eeded, particularly in middle-aged and older patients.
enotype/phenotype relations. A V592fs/8 mutation in
he MyBPC gene is predicted to result in a truncation of the
rotein, including loss of C-terminal myosin and titin
inding sites (36). Konno et al. (21) recently reported that a
issense mutation (Arg820Gln) in the MyBPC gene is
esponsible for HCM with LV systolic dysfunction and
ilation in elderly patients. The function of MyBPC protein
as been elucidated by two recent studies using knockout
ouse models (37,38). Homozygous-null mice in which
ull-length MyBPC protein was absent were viable and had
ignificant cardiac hypertrophy with decreased fractional
hortening. Furthermore, heterozygous MyBPC-null mice
resented a slight-but-significant decrease in MyBPC
mount and developed asymmetric septal hypertrophy (38).
hus, we speculate that a collapse of sarcomere stability
ompensated by residual MyBPC in heterozygous patients
ay occur with advancing age and may lead to impaired
ontractile function in the elderly.
Kokado et al. (39) reported that a Lys183 deletion mutation
n the troponin I gene in HCM patients was associated with
V systolic impairment and dilation in those older than 40
ears of age. Moolman et al. (22) presented that none of the
ubjects with a single-base insertion in exon 25 of the MyBPC
ene showed LV systolic dysfunction and cavity enlargement,
lthough the subjects included several elderly patients. Thus,
nderlying mutations may relate to the progress to the stage of
V dysfunction and dilation. However, the fact that not all
lderly patients with the identical mutation develop “end-
tage” disease suggests that other genetic and/or environmental
actors are involved and underscores the genetic/phenotypic
eterogeneity of HCM. Further investigations are needed to
larify these modifying factors.
tudy limitations. Whether this particular mutation is more
elated to the progression to “end-stage” HCM than the other
utations in MyBPC gene or abnormal MyBPC itself is more
rone to this phenotype than the other sarcomeric abnormal-
ties is unknown. Further studies on the phenotype-genotype
orrelation in terms of longitudinal evolution are needed.
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1743JACC Vol. 46, No. 9, 2005 Kubo et al.
November 1, 2005:1737–43 Lifelong LV Remodeling of HCMonclusions. A founder V592fs/8 mutation in the
yBPC gene was identified in 15 of 94 Japanese families
ith HCM. Elderly patients in particular may evolve to the
end-stage” HCM, characterized by LV systolic dysfunc-
ion, cavity dilation, and irreversible heart failure. Although
he manifestation is late in onset, the clinical course in
atients with this mutation is not benign in the long run
ith progressive LV remodeling with advancing age.
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